NBT Bank N A NY Sells 3,984 Shares of Johnson & Johnson $JNJ

NBT Bank N A NY trimmed its position in Johnson & Johnson (NYSE:JNJ) by 3.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 108,777 shares of the company’s stock after selling 3,984 shares during the quarter. Johnson & Johnson accounts for 1.5% of NBT Bank N A NY’s holdings, making the stock its 12th largest holding. NBT Bank N A NY’s holdings in Johnson & Johnson were worth $20,590,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Clark Asset Management LLC boosted its holdings in Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after purchasing an additional 3,025 shares during the last quarter. Treasurer of the State of North Carolina boosted its holdings in Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after buying an additional 94,957 shares during the last quarter. Avanza Fonder AB increased its holdings in shares of Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after purchasing an additional 6,566 shares during the last quarter. Talbot Financial LLC raised its holdings in shares of Johnson & Johnson by 4.6% during the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock worth $25,667,000 after acquiring an additional 6,143 shares during the period. Finally, Liberty One Investment Management LLC boosted its holdings in Johnson & Johnson by 83.9% in the 3rd quarter. Liberty One Investment Management LLC now owns 366,813 shares of the company’s stock valued at $68,040,000 after purchasing an additional 167,353 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of Johnson & Johnson stock opened at $218.81 on Tuesday. The company’s fifty day moving average is $206.43 and its two-hundred day moving average is $187.62. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $220.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a market capitalization of $527.18 billion, a P/E ratio of 21.12, a PEG ratio of 2.25 and a beta of 0.34.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Wall Street Analyst Weigh In

Several equities analysts have commented on JNJ shares. Raymond James Financial boosted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday, October 20th. Loop Capital set a $190.00 price objective on Johnson & Johnson in a report on Wednesday, October 22nd. Guggenheim increased their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Finally, UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $213.33.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer publicly praised J&J, highlighting its diversified businesses and steady cash flows — a high‑profile endorsement that can attract retail flows and support the stock. Jim Cramer Just Can’t Stop Praising Johnson & Johnson (JNJ)
• Positive Sentiment: J&J is featured in dividend-focused lists as a reliable income name, reinforcing demand from income investors given its yield and long dividend history. 3 Dividend Stocks to Own No Matter Where the Market Moves in 2026
• Positive Sentiment: Zacks highlighted J&J in its investment ideas feature, keeping the stock on investors’ radar as a large-cap healthcare pick. Zacks Investment Ideas feature highlights: Netflix, Intel and Johnson & Johnson
• Neutral Sentiment: Benzinga flags a “$10 billion test” in J&J’s 2026 outlook — management’s guidance and 2026 execution will be pivotal in the Q4 print and could swing sentiment either way. Johnson & Johnson’s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4
• Neutral Sentiment: Analyst previews (Zacks, TipRanks, others) show mixed views: strong pharma and MedTech momentum but pressure from Stelara biosimilar competition and China headwinds — earnings will clarify the balance. Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
• Neutral Sentiment: Pre‑earnings pieces (TipRanks/MarketBeat) note analysts expect modest revenue growth into Q4; some investors are using hedged exposure strategies ahead of the release to limit risk. Is Johnson & Johnson (JNJ) Stock a Buy Ahead of Q4 Earnings?
• Negative Sentiment: Seeking Alpha warns that a sizable 2025 downgrade has tempered expectations; lowered growth assumptions can keep a lid on valuation and increase downside risk if guidance disappoints. Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)
• Negative Sentiment: Bank of America reiterated a Hold rating, signaling limited near‑term upside in analysts’ view and potentially constraining momentum from bullish headlines. Bank of America Securities Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.